These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Engle JA; Kolesar JM Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236 [TBL] [Abstract][Full Text] [Related]
4. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma. Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921 [TBL] [Abstract][Full Text] [Related]
5. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644 [TBL] [Abstract][Full Text] [Related]
6. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Wu SG; Liu YN; Tsai MF; Chang YL; Yu CJ; Yang PC; Yang JC; Wen YF; Shih JY Oncotarget; 2016 Mar; 7(11):12404-13. PubMed ID: 26862733 [TBL] [Abstract][Full Text] [Related]
7. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma. Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441 [TBL] [Abstract][Full Text] [Related]
8. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma]. Sárosi V; Balikó Z Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450 [TBL] [Abstract][Full Text] [Related]
9. Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Yamaoka T; Ohmori T; Ohba M; Arata S; Murata Y; Kusumoto S; Ando K; Ishida H; Ohnishi T; Sasaki Y Mol Cancer Res; 2017 Jul; 15(7):915-928. PubMed ID: 28289161 [TBL] [Abstract][Full Text] [Related]
10. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487 [TBL] [Abstract][Full Text] [Related]
11. The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Kim Y; Ko J; Cui Z; Abolhoda A; Ahn JS; Ou SH; Ahn MJ; Park K Mol Cancer Ther; 2012 Mar; 11(3):784-91. PubMed ID: 22228822 [TBL] [Abstract][Full Text] [Related]
12. Management and future directions in non-small cell lung cancer with known activating mutations. Gerber DE; Gandhi L; Costa DB Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124 [TBL] [Abstract][Full Text] [Related]
13. The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy. Yang CJ; Hung JY; Tsai MJ; Wu KL; Liu TC; Chou SH; Lee JY; Hsu JS; Huang MS; Chong IW BMC Pharmacol Toxicol; 2017 May; 18(1):21. PubMed ID: 28486985 [TBL] [Abstract][Full Text] [Related]
14. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911 [TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Bean J; Riely GJ; Balak M; Marks JL; Ladanyi M; Miller VA; Pao W Clin Cancer Res; 2008 Nov; 14(22):7519-25. PubMed ID: 19010870 [TBL] [Abstract][Full Text] [Related]
16. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor ( Han JY; Lee KH; Kim SW; Min YJ; Cho E; Lee Y; Lee SH; Kim HY; Lee GK; Nam BH; Han H; Jung J; Lee JS Cancer Res Treat; 2017 Jan; 49(1):10-19. PubMed ID: 27188206 [TBL] [Abstract][Full Text] [Related]
17. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165 [TBL] [Abstract][Full Text] [Related]
18. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086 [TBL] [Abstract][Full Text] [Related]
19. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer. Marquez-Medina D; Popat S Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834 [TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]